PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04601-3
Abstract: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in… read more here.
Keywords: response; ppq; recist; non responders ... See more keywords
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-04873-0
Abstract: Purpose In March 2014, we reported the activity and safety of 177 Lu-DOTA-octreotate peptide receptor radionuclide therapy (Lu-PRRT) at two different dosages (18.5 GBq and 27.5 GBq in 5 cycles) in patients with progressive metastatic gastrointestinal neuroendocrine tumors… read more here.
Keywords: phase; year follow; gastrointestinal neuroendocrine; prrt ... See more keywords
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-021-01037-7
Abstract: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on… read more here.
Keywords: radionuclide therapy; prrt; receptor radionuclide; receptor ... See more keywords
Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02534-8
Abstract: Small intestinal neuroendocrine tumours (siNETs) with a Ki-67 proliferation index between 3 and 20% belong to WHO grade 2. Response to treatment may be monitored by blood chromogranin A (CgA) and urine 5-hydroxyindoleacetic acid (5HIAA).… read more here.
Keywords: small intestinal; treatment; prrt; neuroendocrine tumours ... See more keywords
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
Sign Up to like & getrecommendations! Published in 2018 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000000926
Abstract: Background and aims Functioning and symptomatic disease resistant to conventional therapies constitutes a subset amongst neuroendocrine tumors (NETs) that are commonly considered for peptide receptor radionuclide therapy (PRRT). The aim of this study was to… read more here.
Keywords: progressive symptomatic; prrt; neuroendocrine tumors; receptor radionuclide ... See more keywords
177Lu-DOTATATE Theranostics
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004599
Abstract: Purpose Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy 68Ga-DOTATATE PET uptake data and other baseline… read more here.
Keywords: pet uptake; 177lu dotatate; dotatate; pretherapy 68ga ... See more keywords
Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Case Reports in Oncology"
DOI: 10.1159/000496335
Abstract: The field of theranostics is a new nuclear medicine tool being utilized in the treatment of different types of cancers. It couples receptor-specific based imaging predicting and guiding response to receptor-specific based radionuclide therapies. For… read more here.
Keywords: therapy; 177lu dotatate; dotatate; prrt ... See more keywords
Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
Sign Up to like & getrecommendations! Published in 2020 at "EJNMMI Physics"
DOI: 10.1186/s40658-020-00303-0
Abstract: Dead time may affect the accuracy of quantitative SPECT (QPSECT), and thus of dosimetry. The aim of this study was to quantify the effect of dead time on 177Lu-QSPECT and renal dosimetry following peptide receptor… read more here.
Keywords: prrt; kidney dosimetry; time; dead time ... See more keywords
Real-world analysis of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16701
Abstract: e16701Background: PRRT received FDA approval in 2018 for treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) based on NETTER-1 trial data that include... read more here.
Keywords: real world; world analysis; treatment; prrt ... See more keywords
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.941832
Abstract: Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation… read more here.
Keywords: neuroendocrine tumors; added 177; prrt; treatment ... See more keywords
Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14030584
Abstract: Simple Summary Neuroendocrine neoplasms have been usually described as infrequent tumors, but their incidence has been rising over time. [177Lu]Lu-DOTA-TATE (PRRT-Lu) was approved by the European Medicines Agency and by the Food and Drug Administration… read more here.
Keywords: receptor radionuclide; 177lu dota; peptide receptor; radionuclide therapy ... See more keywords